Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan

Vadadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). This phase 3, open‐label, 24‐week single‐arm study evaluated the efficacy and safety of vadadustat in 42 Japanese CKD patients with anemia undergoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Nangaku, Masaomi, Kondo, Kazuoki, Takabe, Souichirou, Ueta, Kiichiro, Kaneko, Genki, Otsuka, Makiko, Kawaguchi, Yutaka, Komatsu, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451920/
https://www.ncbi.nlm.nih.gov/pubmed/33283981
http://dx.doi.org/10.1111/1744-9987.13611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451920/
https://www.ncbi.nlm.nih.gov/pubmed/33283981
http://dx.doi.org/10.1111/1744-9987.13611

Ejemplares similares